Skip to content

Efectivity of Non-invasive Neuromodulation in Parasympathic Nervous System and Vascular System

Efectivity of Non-invasive Neuromodulation in Parasympathic Nervous System and Vascular System

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT06320171
Enrollment
40
Registered
2024-03-20
Start date
2024-04-01
Completion date
2024-06-30
Last updated
2025-01-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hypertension

Brief summary

The aim of the present study is to evaluate the acute effect immediately after the application of the NESA treatment in healthy participants in vascular sonographic variables measured in the left CCA such as the LD, IMT and PSV, as well as systolic (sBP) and diastolic blood (dBP) pressure and heart rate (HR). The investigators hypothesized that NESA application will induce a direct influence in the vascular tone through the stimulation of the ANS and the parasympathetic nerve system. This premise is based on the fact that non-invasive NESA neuromodulation enhance the autonomic regulation of vascular tone and endothelial function.

Detailed description

The aim of the present study is to evaluate the acute effect immediately after the application of the NESA treatment in healthy participants in vascular sonographic variables measured in the left CCA such as the LD, IMT and PSV, as well as systolic (sBP) and diastolic blood (dBP) pressure and heart rate (HR). We hypothesize that NESA application will induce a direct influence in the vascular tone through the stimulation of the ANS and the parasympathetic nerve system. This premise is based on the fact that non-invasive NESA neuromodulation enhance the autonomic regulation of vascular tone and endothelial function.A total sample of forty participants (N = 40; mean age 26.6 ± 6.7 years) were recruited for participation in the study. Prior to entering the study, all participants received information about the study and signed a consent form to participate. The study subjects were divided into two equally distributed groups (A: NESA = 20; B: Placebo = 20) and were blinded to the study group allocation. Participants in the placebo group underwent the same procedural phases as those in the intervention group. However, for the placebo group, the device was set to deliver a low-intensity current below the sensory threshold, effectively rendering it inactive from the participants' perspective.

Interventions

Direct stimulation of the autonomic nervous system was achieved using Program 7 (P7) of the device, with a directional electrode positioned at the level of the C7 spinous process. P7 delivered a biphasic polarity current with oscillatory frequencies ranging from 1.92 to 14.29 Hz and variable intensities between 0.1 and 0.9 mA.

OTHERPlacebo

The placebo group followed the same procedure, except that no current was applied during their 20-minute session.

Sponsors

Universidad Europea de Madrid
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
OTHER
Masking
SINGLE (Subject)

Eligibility

Sex/Gender
ALL
Age
18 Years to 65 Years
Healthy volunteers
Yes

Inclusion criteria

Inclusion: \- Age between: 18-55 years, both sexes. Exclusion: * Cardiovascular disease. * Specific pharmacology. * Hypertension. * Diabetes. * Systemic diseases.

Design outcomes

Primary

MeasureTime frameDescription
Systolic and diastolic Blood Pressure:before the intervention, and 10 minutes after the interventionThe pressure in the arteries during the contraction of the heart muscle. Measured with sphingomanometer.
Heart rateBefore the intervention, and 10 minutes after the interventionHearbears per minute

Secondary

MeasureTime frameDescription
Ultrasonographic variables:Thickness of the common carotidBefore the intervention, and 10 minutes after the interventionThickness of the common carotid
Ultrasonographic variables: Cross-sectional area of the jugular veinBefore the intervention, and 10 minutes after the interventionCross-sectional area of the jugular vein
Cortisol measurementBefore the intervention, and 10 minutes after the interventionMeasure of cortisol level.
Ultrasonographic variables:Peak systolic velocity.Before the intervention, and 10 minutes after the interventionPeak systolic velocity.
Ultrasonographic variables:Cross-sectional area of the common carotidBefore the intervention, and 10 minutes after the interventionCross-sectional area of the common carotid

Countries

Spain

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026